The nose bleed section is right.
Full disclosure:
My low price is 43 cents. I think I would have gotten 39 cents except I was in the mens' room throwing up. So, on a personal note it was pleasant two days ago when the stock moved more than .43 cents in one day.
But , when I get past the petty self congrats and start to think more seriously once again, I feel that this whole move is still trivial.
In my well formed opinion, there are days coming when the move will be larger than "todays'" market cap.
Just do the math and the comparisons and the market sizes and forget about how you "feel about things." Get objective only.
The Chicago Symposium starts on Sept 6th. That is an interesting date in that it is exactly eleven months from the 2nd line NSCLC enrollment completion date. IMO there is a 95% probability that the average clinical patient was enrolled between 2-5 months before the completion date. If MOS is not achieved by the start of the symposium it is probably 13-16 months in duration. That would be historic in the many ways we have previously discussed.
What PPHM is not disclosing is data on CRs' and I am eagerly awaiting any news in this area. You all understand my concept of "Volume" in the way bavi approaches the cancer market. The way you multiply volume is with "hope".
CRs' give people hope.
If they can live longer with fewer side effects, that's terrific.
If they have 5-10% chance of CR that's much more than terrific that is "hope". If you have hope you can take the volume and multiply it by a factor yet to be determined.
BTW--PPHM will not need a partner nor an MOS achieved date to schedule the end of phase II conference with the FDA IMO. Those two details can be taken care of during the 60 day period leading to the meeting or afterwards.
Best Regards,
RRdog
News 
Market Data 
Discover 
AI
